About maxygen Products Science & Technology News Investors Careers Contact Us

Protein Therapeutics News

October 10, 2011

Maxygen Announces Final Rejection of All Claims of Amgen ‘804 Patent in Inter Partes Reexamination Proceeding

REDWOOD CITY, Calif., October 10, 2011 ─ Maxygen,...
More >>

January 19, 2010

Perseid Achieves Preclinical Milestone under Collaboration with Astellas for CTLA-4 Program

REDWOOD CITY, Calif., January 19, 2010 ─ Maxygen, Inc. (Nasdaq: M...
More >>

July 14, 2009

Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients

-MAXY-G34 was Effective in Reducing...
More >>

June 30, 2009

Maxygen Announces Joint Venture with Astellas to Develop Protein Pharmaceuticals

-Maxygen to Contribute R&D Operations and Assets to Newly-Fo...
More >>

October 22, 2008

Maxygen Announces Plans to Reduce Spending and Revise Corporate Strategy

-Phase III Manufacturing for MAXY-G34 Delayed until Partner is ...
More >>

September 18, 2008

Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation

-Astellas to Receive Rights to Commercialize MAXY-4 CTLA4-Ig Can...
More >>

July 2, 2008

Bayer HealthCare and Maxygen Announce Hematology Agreement

-Portfolio of hemophilia drug candidates in...
More >>

June 11, 2008

Maxygen Receives Approval for Clinical Trial of Factor VIIa in the United Kingdom

More >>

January 7, 2008

Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF

Redwood CityMore >>

November 26, 2007

Maxygen Updates Status of MAXY-alpha Program

REDWOOD CITY, Calif., November 26...
More >>

September 21, 2007

Maxygen Announces Hold on MAXY-alpha Development Program

More >>

July 2, 2007

Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients

More >>

April 10, 2007

Maxygen to Present Review of G-CSF Clinical Program Live at NASDAQ MarketSite® Tuesday, April 17, 8:00 a.m. EST

Redwood City, Calif., April 10, 2007 – Maxygen, Inc. (Nasd...
More >>

March 13, 2007

Maxygen Announces End of Co-Development Agreement

Redwood City, Calif., March 13, 2007 - Maxygen, Inc...
More >>

November 7, 2006

Maxygen's Next-Generation Interferon Alpha Enters Phase Ia Clinical Trial
Redwood City, Calif., November 7, 2006 – Maxygen, Inc. (Nasdaq: MAXY...
More >>

September 5, 2006

Maxygen Initiates Phase I Clinical Trial for Maxy-G34
Redwood City, Calif., September 5, 2006 – Maxygen, Inc. (Nasdaq: MAX...
More >>

May 9, 2006

Maxygen Achieves Milestone in Alliance with Roche for Factor VIIa Therapeutics
Redwood City, Calif., May 9, 2006—Maxygen, Inc. (Nasdaq: MAXY) today...
More >>

December 15, 2005

Roche and Maxygen to Co-Develop Recombinant Factor VIIa Therapeutics for Acute Bleeding

NUTLEY, NJ and Redwood City, Calif., December 15, 2005 â...
More >>

December 14, 2005

Maxygen Announces Achievement of Milestone in Roche Alliance
Redwood City, Calif., December 13, 2005 ? Maxygen, Inc. (Nasdaq: MAXY)...
More >>

March 30, 2005

Maxygen Announces Achievement of Milestone in Alliance with Roche
Redwood City, Calif., March 30, 2005 ? Maxygen, Inc. (Nasdaq: MAXY) an...
More >>

December 3, 2004

Maxygen announces new development program and product development prioritization
Redwood City, Calif., December 3, 2004 ? Maxygen, Inc. (Nasdaq: MAXY) ...
More >>

September 9, 2004

Maxygen and Rentschler Sign Agreement to Manufacture Novel G-CSF
Redwood City, Calif., Laupheim, Germany, September 9, 2004 -- Maxygen,...
More >>

July 27, 2004

Maxygen Reports Second Quarter 2004 Financial Results
Redwood City, Calif., July 27, 2004 – Maxygen, Inc. (Nasdaq: MAXY) tod...
More >>

June 8, 2004

Maxygen and Biovitrum Sign Agreement to Manufacture Optimized Beta Interferon for Phase I and II Clinical Trials
Redwood City, Calif., Stockholm, Sweden June 8, 2004 Maxygen, Inc....
More >>

May 22, 2003

Roche and Maxygen Establish Broad Alliance To Develop and Commercialize Next-Generation Interferon Alpha and Beta Products
Basel, Switzerland and Redwood City, Calif., May 22, 2003 – Roche and ...
More >>

October 7, 2002

Intermune and Maxygen Announce Progress in Alliance to Develop Once-Weekly Actimmune
InterMune, Inc., (Nasdaq: ITMN) and Maxygen Holdings Ltd., a wholly-ow...
More >>

July 24, 2002

Maxygen Announces Appointment of Paul Spence, D.Phil.,to Senior Vice President of Research and Development, Human Therapeutics
Redwood City, Calif., July 24, 2002 – Maxygen, Inc. (Nasdaq: MAXY) ann...
More >>

February 21, 2002

Maxygen Announces Advancement of Improved Interferon Beta for Multiple Sclerosis
Redwood City, Calif., February 21, 2002 – Maxygen, Inc. (Nasdaq: MAXY)...
More >>

January 8, 2002

Celltech and Maxygen Enter Into Antibody Collaboration
Redwood City, CA and Slough, England– January 8, 2002 - Celltech Group...
More >>

October 9, 2001

Maxygen Announces Advancement of Human Therapeutics Candidates
Redwood City, Calif., October 9, 2001 – Maxygen, Inc. (Nasdaq: MAXY) a...
More >>

September 5, 2001

InterMune and Maxygen Form Collaboration to Develop Next-Generation Interferon Gamma Products
Redwood City and Brisbane, Calif., September 5, 2001 – Maxygen Holding...
More >>

September 19, 2000

Maxygen and H. Lundbeck A/S Enter into Research and Development Agreement
Redwood City, Calif., September 19, 2000 - Maxygen ApS, a wholly owned...
More >>

September 15, 2000

Maxygen and Shearwater Enter Into Strategic Protein Pharmaceutical Alliance
Redwood City, Calif., and Huntsville, Ala., September 15, 2000 – Maxyg...
More >>

August 10, 2000

Maxygen Completes Acquisition of ProFound Pharma A/S
Redwood City, Calif., August 10, 2000 – Maxygen (MAXY – Nasdaq) today ...
More >>

April 12, 2000

Maxygen to Acquire ProFound Pharma A/S to Expand its Position in Protein Pharmaceuticals
Redwood City, Calif., April 27, 2000 - Maxygen, Inc. (Nasdaq: MAXY) to...
More >>

February 28, 2000

Maxygen Announces Cooperative Research and Development Agreement with The National Cancer Institute for Novel Protein Pharmaceuticals
Redwood City, Calif., February 28, 2000 – Maxygen (MAXY – NASDAQ) anno...
More >>

Return to Protein Therapeutics